WallStSmart

Novartis AG ADR (NVS)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 574372% more annual revenue ($56.58B vs $9.85M). NVS leads profitability with a 23.9% profit margin vs -10.9%. NVS earns a higher WallStSmart Score of 49/100 (D+).

NVS

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

WOK

Avoid

35

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued

Intrinsic value data unavailable for WOK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

WOK1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

WOK4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Market CapQuality
$118,5803/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Revenue GrowthGrowth
-14.4%2/10

Revenue declined 14.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : WOK

The strongest argument for WOK centers on Price/Book.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : WOK

The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.

Key Dynamics to Monitor

NVS profiles as a declining stock while WOK is a turnaround play — different risk/reward profiles.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (49/100 vs 35/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

WORK Medical Technology Group LTD Ordinary Shares

HEALTHCARE · MEDICAL DEVICES · USA

WORK Medical Technology Group Ltd is a prominent player in the medical technology sector, focusing on the research, development, and commercialization of innovative healthcare solutions. With a strong emphasis on advanced medical devices, the company strives to improve patient outcomes and tackle significant challenges in global healthcare. Its dedication to quality, innovation, and a diverse product portfolio not only enhances its market position but also aligns with the interests of institutional investors seeking opportunities in transformative healthcare advancements. As the demand for effective medical technologies continues to rise, WORK is well-positioned for sustained growth and value creation.

Visit Website →

Want to dig deeper into these stocks?